Sign in
ATOS Stock Price, Chart, Stats & News
Atossa Therapeutics, Inc.
Save
Atossa Therapeutics, Inc. (ATOS) does not currently pay a dividend.
18.95M
Market cap
–
Current P/E
7.04x
Forward P/E
ATOS chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -73.03% |
ROE | -65.56% |
D/E | – |
Interest coverage ratio | – |
ATOS valuation
P/E | – |
P/S | – |
P/B | 1.03x |
P/CF | -1.37x |
P/FCF | -1.36x |
P/OCF | -1.37x |
PEG | 0.08x |
EV multiple | -2.24x |
About
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen.
Similar securities
Based on sector and market capitalization
Report issue